Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1143532-39-1
Formula :	C₂₁H₂₅ClN₆O₂
M.W :	428.92
SMILES Code :	O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO
Synonyms :	AZD5363
MDL No. :	MFCD22628785
InChI Key :	JDUBGYFRJFOXQC-KRWDZBQOSA-N
Pubchem ID :	25227436

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

T47D	0.01 –10μM	72 h	To evaluate the inhibitory effect of Capivasertib on T47D cells, results showed that T47D cells had an IC50 value of 2.1 μM and were more sensitive to Capivasertib than MCF-7 cells.	Br J Cancer. 2024 Nov;131(9):1543-1554.
MCF-7	0.01 –10μM	72 h	To evaluate the inhibitory effect of Capivasertib on MCF-7 cells, results showed that MCF-7 cells had an IC50 value of 7.5 μM and were less sensitive to Capivasertib than T47D cells.	Br J Cancer. 2024 Nov;131(9):1543-1554.
Onc-negativeRAS/PI3K murine cell lines	10 μM	2 days	To evaluate the effect of Capivasertib on cell proliferation and apoptosis. Results showed that Capivasertib significantly inhibited cell proliferation and induced apoptosis.	Cancer Res. 2022 Apr 15;82(8):1589-1602.
MCF-7	500 nM	6 days	To evaluate the growth inhibitory effect of Capivasertib in MCF-7 cells, the results showed that the triple combination (fulvestrant, CDK4/6i, and AKTi) significantly inhibited the growth of fulvestrant-resistant cells	Nat Commun. 2021 Aug 25;12(1):5112.
T47D	200 nM	6 days	To evaluate the growth inhibitory effect of Capivasertib in T47D cells, the results showed that the triple combination (fulvestrant, CDK4/6i, and AKTi) significantly inhibited the growth of fulvestrant-resistant cells	Nat Commun. 2021 Aug 25;12(1):5112.
ZR-75-1	150 nM	6 days	To evaluate the growth inhibitory effect of Capivasertib in ZR-75-1 cells, the results showed that the triple combination (fulvestrant, CDK4/6i, and AKTi) significantly inhibited the growth of fulvestrant-resistant cells	Nat Commun. 2021 Aug 25;12(1):5112.
AN3-CA	1 µM	74 h	To validate the combination activity of Capivasertib with AZD5991 in endometrial cancer cells, results showed induction of apoptosis in AN3-CA and MFE-296 cells.	Cancer Discov. 2024 May 1;14(5):846-865.
MFE-296	1 µM	74 h	To validate the combination activity of Capivasertib with AZD5991 in endometrial cancer cells, results showed induction of apoptosis in AN3-CA and MFE-296 cells.	Cancer Discov. 2024 May 1;14(5):846-865.
HCC70	500 nM	4 days	To evaluate the sensitivity of HCC70 cells to Capivasertib, the results showed that Capivasertib significantly inhibited cell proliferation.	Oncogene. 2022 Nov;41(46):5046-5060.
EVSA-T	1 µM	4 days	To evaluate the sensitivity of EVSA-T cells to Capivasertib, the results showed that Capivasertib significantly inhibited cell proliferation.	Oncogene. 2022 Nov;41(46):5046-5060.
SNU-1196-GR	2 μM	72 h	To evaluate the sensitivity of SNU-1196-GR cells to Capivasertib, results showed that Capivasertib reduced the IC50 value of GEM.	Int J Biol Sci. 2023 May 21;19(9):2772-2786.
SSP-25-GR	2 μM	24 h	To evaluate the effect of Capivasertib on hENT1 expression in SSP-25-GR cells, results showed that Capivasertib enhanced hENT1 expression.	Int J Biol Sci. 2023 May 21;19(9):2772-2786.
MDA-MB-231 cells	0.1 μM	48 h	To investigate the effect of Capivasertib on DOX-induced cell death in DNAJC12-overexpressing cells, results showed that Capivasertib significantly decreased cell viability in the DNAJC12-overexpressing group, approaching the level observed with DOX treatment alone in the negative control group.	Redox Biol. 2024 Apr;70:103035.
MCF-7 cells	0.1 μM	48 h	To investigate the effect of Capivasertib on DOX-induced cell death in DNAJC12-knockdown cells, results showed that Capivasertib significantly decreased cell viability in the negative control group, approaching the level observed with DOX treatment alone in the DNAJC12 knockdown group.	Redox Biol. 2024 Apr;70:103035.

SCID mice	MCF7 xenograft model	Oral	150 mg/kg	Twice daily for 28 days	AZD5363 treatment significantly reduced (22%) mean tumor volume (MTV) of MCF7 parental tumors whereas it had no effect on MCF7 CR2.5 tumors, at day 18 of treatment.	Oncotarget. 2018 Apr 20;9(30):21444-21458.
Mice	TC mice	Oral	100 mg/kg	Daily for eight days, stopped for two days for recovery, and continued for two more days	To evaluate the effect of Capivasertib alone or in combination with RMC-4550 on tumor burden. Results showed that Capivasertib alone was ineffective in vivo, but the combination with RMC-4550 significantly reduced tumor burden.	Cancer Res. 2022 Apr 15;82(8):1589-1602.
Mice	Breast cancer xenograft model	Oral	100 mg/kg	5 days per week for 7 weeks	To evaluate the anti-tumor effect of Capivasertib in a breast cancer xenograft model, the results showed that the triple combination (fulvestrant, CDK4/6i, and AKTi) significantly inhibited tumor growth and prevented tumor recurrence	Nat Commun. 2021 Aug 25;12(1):5112.
Mice	PTEN-deficient prostate cancer PDX model	Intraperitoneal injection	2.5 mg/kg	Daily, continuous treatment	To evaluate whether the CX3CR1 inhibitor JMS-17-2 could sensitize PTEN-deficient prostate cancer to the AKT inhibitor Capivasertib. The results showed that JMS-17-2 significantly enhanced the inhibitory effect of Capivasertib on PDX growth.	J Clin Invest. 2024 May 23;134(14):e175949
Mice	NOMO-1 xenograft model	Oral	10 mg/kg	Twice daily for 28 days	To evaluate the in vivo activity of Capivasertib with AZD5991 in the NOMO-1 xenograft model, results showed significant tumor growth inhibition.	Cancer Discov. 2024 May 1;14(5):846-865.
Female nude mice	HCC70 tumor xenograft model	Oral	130 mg/kg	Twice daily for 4 days	To evaluate the anti-tumor activity of Capivasertib in combination with AZD5991 in the HCC70 tumor xenograft model, the results showed that the combination significantly inhibited tumor growth.	Oncogene. 2022 Nov;41(46):5046-5060.
BALB/c nude mice	SNU-1196-GR xenograft model	Oral gavage	100 mg/kg	Five times per week for 3 weeks	To evaluate the effect of Capivasertib in combination with GEM on tumor growth in the SNU-1196-GR xenograft model, results showed that the combination treatment significantly inhibited tumor growth.	Int J Biol Sci. 2023 May 21;19(9):2772-2786.
BALB/c nude mice	MDA-MB-231 cell-derived xenograft model	Intraperitoneal injection	50 mg/kg	Every three days for a total of 5 injections	To investigate the reversal effect of Capivasertib on DNAJC12-induced DOX resistance, results showed that the combination of Capivasertib and DOX significantly reduced tumor volume in the DNAJC12-overexpressing group, reversing DOX resistance.	Redox Biol. 2024 Apr;70:103035.

{[proInfo.proName]}

CAS No.: 1143532-39-1

{[proInfo.proName]}

CAS No.: 1143532-39-1

Alternative Products

Product Details of Capivasertib

Safety of Capivasertib

Related Pathways of Capivasertib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01353781	Advanced Solid Malignancy\|Adva... More >>nced Solid Tumor Less <<	PHASE1	COMPLETED	2025-07-14	Research Site, Chuo-ku, Japan
NCT06613516	Breast Cancer\|Oestrogen Recept... More >>or Positive Breast Cancer Less <<	PHASE2	NOT_YET_RECRUITING	2027-11-01	Imperial College Healthcare Tr... More >>ust, London, United Kingdom Less <<
NCT02077569	Invasive Breast Cancer	PHASE2	COMPLETED	2017-02-21	Royal Derby Hospital, Derby, D... More >>erbyshire, DE22 3DT, United Kingdom\|Plymouth Hospitals NHS Trust, Derriford, Plymouth, Devon, PL6 8DH, United Kingdom\|Royal Bournemouth Hospital, Bournemouth, Dorset, BH7 7DW, United Kingdom\|Poole Hospital NHS Foundation Trust, Poole, Dorset, BH15 2JB, United Kingdom\|Leicester Royal Infirmary, Leicester, Leicestershire, LE1 5WW, United Kingdom\|Western General Hospital, Edinburgh, Lothian, EH4 2XU, United Kingdom\|Royal Liverpool University Hospital, Liverpool, Merseyside, L7 8XP, United Kingdom\|Kingsmill Hospital, Sutton-in-Ashfield, Nottinghamshire, NG17 4JL, United Kingdom\|Sheffield Cancer Research Centre, Sheffield, South Yorkshire, S10 2SJ, United Kingdom\|University Hospital Birmingahm, Birmingham, West Midlands, B15 2TT, United Kingdom\|Leeds St James Institue of Oncology, Leeds, West Yorkshire, LS9 7TF, United Kingdom Less <<
NCT05008055	Relapsed or Refractory B-cell ... More >>Non-Hodgkin Lymphoma Less <<	PHASE2	COMPLETED	2024-10-25	Research Site, Duarte, Califor... More >>nia, 91010, United States\|Research Site, Los Angeles, California, 90095, United States\|Research Site, Houston, Texas, 77030, United States\|Research Site, Victoria, British Columbia, V8R 6V5, Canada\|Research Site, Aarhus N, DK8200, Denmark\|Research Site, Poitiers, 86021, France\|Research Site, Villejuif Cedex, 94805, France\|Research Site, Busan, 49241, Korea, Republic of\|Research Site, Seoul, 06351, Korea, Republic of\|Research Site, Seoul, 3722, Korea, Republic of\|Research Site, Badalona, 08003, Spain\|Research Site, Barcelona, 8035, Spain\|Research Site, Madrid, 28040, Spain\|Research Site, Madrid, 28046, Spain\|Research Site, Cambridge, CB2 0QQ, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom\|Research Site, Sutton, SM2 5PT, United Kingdom Less <<
NCT04439123	Advanced Lymphoma\|Advanced Mal... More >>ignant Solid Neoplasm\|Hematopoietic and Lymphoid Cell Neoplasm\|Refractory Lymphoma\|Refractory Malignant Solid Neoplasm\|Refractory Multiple Myeloma Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2025-03-05	ECOG-ACRIN Cancer Research Gro... More >>up, Philadelphia, Pennsylvania, 19103, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.33mL 0.47mL 0.23mL	11.66mL 2.33mL 1.17mL	23.31mL 4.66mL 2.33mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed